Showing results (161-170 of 241) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2017
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care ActKenneth L Kehl, Cheryl P Fullmer, Siqing Fu, et al.
Molecular Cancer Therapeutics|July 29, 2016
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted TherapeuticsJennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
NPJ Precision Oncology|April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyJacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Cancer Research Communications|December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid MalignanciesVivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid TumorsGerald S Falchook, Razelle Kurzrock, Hesham M Amin, et al.
Experimental Hematology & Oncology|December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumorsKyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Scientific Reports|May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiencesShuyang Yao, Funda Meric-Bernstam, David Hong, et al.
Clinical Breast Cancer|July 29, 2014
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unitDebora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.
Pageof 25